Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma
NCT03718338 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2
Last updated 2020-12-10
Summary
This trial studies the mechanisms of metabolic and hormone action on plaque formation in brain and carotid vessels in patients with prostate adenocarcinoma. Studying the biomarkers in the laboratory may help doctors know the impact of androgen deprivation on metabolic, brain and cardiovascular endpoints.
Conditions
- Prostate Adenocarcinoma
Interventions
- PROCEDURE
-
Evaluation
Undergo clinical evaluations
- OTHER
-
Quality-of-Life Assessment
Ancillary studies
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH - lead OTHER
Principal Investigators
-
Evan Yu · Fred Hutch/University of Washington Cancer Consortium
Eligibility
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-10-08
- Primary Completion
- 2020-03-12
- Completion
- 2020-03-12
Countries
- United States
Study Locations
More Related Trials
-
Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
NCT03516812 ·Status: COMPLETED ·Phase: PHASE2
-
A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy
NCT01732549 ·Status: TERMINATED ·Phase: PHASE2
-
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
NCT00936390 ·Status: COMPLETED ·Phase: PHASE3
-
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT01503229 ·Status: COMPLETED ·Phase: PHASE2
-
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
NCT00651326 ·Status: TERMINATED ·Phase: PHASE3
-
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
NCT00567580 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer
NCT00551044 ·Status: COMPLETED ·Phase: NA
-
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
NCT02913196 ·Status: COMPLETED ·Phase: PHASE1
-
Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer
NCT03503344 ·Status: COMPLETED ·Phase: PHASE2
-
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
NCT00110162 ·Status: UNKNOWN ·Phase: PHASE3
-
Hormone Therapy in Treating Patients With Advanced Prostate Cancer
NCT00003026 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)
NCT00514917 ·Status: TERMINATED ·Phase: PHASE3
-
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
NCT00004054 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT02257736 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02565901 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly
NCT00161252 ·Status: WITHDRAWN
-
Study With [225Ac]Ac-FL-020 in mCRPC Participants
NCT06492122 ·Status: RECRUITING ·Phase: PHASE1
-
Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent
NCT01303692 ·Status: COMPLETED
-
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
NCT03360721 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
NCT05534646 ·Status: RECRUITING ·Phase: PHASE2
-
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT
NCT05983198 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
NCT00002924 ·Status: COMPLETED
-
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
NCT00243646 ·Status: TERMINATED ·Phase: PHASE3
-
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
NCT00172055 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
NCT02849990 ·Status: COMPLETED ·Phase: PHASE2